3 completed, 2 recruiting, 2 unknown. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Recruiting 2, Unknown 2 |
| Phase 1 | 1 | Completed 1 |
Follow Memory Impairment: new trials by email Literature Review of Memory Impairment trials Research Report on Memory Impairment
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy Lithium, Placebo - Cognitive Impairment, Cognitive Decline | Phase 2 | Recruiting | Region Stockholm | 84 | 2024-02-16 | 2024-04-12 |
| Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment NITESGON, Lidocaine / Prilocaine Topical Cream, C5/C6 stimulation - Mild Cognitive Impairment, Memory Impairment | Phase 1 / Phase 2 | Completed | University of Dublin, Trinity College | 80 | 2022-09-01 | 2026-01-26 |
| Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease COT, Sham - Mild Cognitive Impairment, Early Alzheimer's Disease | Phase 2 | Unknown | Evon Medics LLC | 200 | 2021-11-15 | 2022-05-17 |
| Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X) CORT108297, Placebo - Mild Cognitive Impairment, Alzheimer Disease | Phase 2 | Recruiting | Johns Hopkins University | 52 | 2021-06-28 | 2026-07-13 |
| Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease Levetiracetam, Placebo - Parkinson Disease, Mild Cognitive Impairment | Phase 2 | Unknown | The University of Queensland | 28 | 2021-02-09 | 2024-09-25 |
| Effect of Insulin Sensitizer Metformin on AD Biomarkers Metformin, Placebos - Alzheimer's Disease, Vascular Dementia | Phase 2 | Completed | University of Pennsylvania | 20 | 2013-01-01 | 2017-09-21 |
| Vilazodone for Corticosteroid-Induced Memory Impairment Vilazodone, Placebo, Hydrocortisone - Memory Impairment | Phase 2 | Completed | University of Texas Southwestern Medical Center | 24 | 2012-12-01 | 2019-04-11 |
Memory Disorders (7) · Cognitive Dysfunction (5) · Alzheimer Disease (3) · Dementia (2) · Brain Neoplasms (1) · Dementia, Vascular (1) · Parkinson Disease (1) · Radiation Injuries (1)
Nervous System Diseases (7) · Neurobehavioral Manifestations (7) · Neurologic Manifestations (7) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7) · Mental Disorders (6) · Neurocognitive Disorders (6) · Brain Diseases (5) · Central Nervous System Diseases (5) · Cognition Disorders (5) · Neurodegenerative Diseases (4) · Tauopathies (3) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Basal Ganglia Diseases (1)
Anesthetics, Local (1) · CORT 108297 (1) · Hydrocortisone (1) · Levetiracetam (1) · Lidocaine (1) · Lithium (1) · Metformin (1) · Transcutaneous Electric Nerve Stimulation (1) · Vilazodone Hydrochloride (1) · lithium sulfate (1) · salicylhydroxamic acid (1)
Evon Medics LLC (1) · Johns Hopkins University (1) · Region Stockholm (1) · The University of Queensland (1) · University of Dublin, Trinity College (1) · University of Pennsylvania (1) · University of Texas Southwestern Medical Center (1)
United States (4) · Australia (1) · Ireland (1) · Sweden (1)
Cynthia A Munro, PhD (1) · E. Sherwood Brown, M.D., Ph.D. (1) · Evaristus Nwulia, MD (1) · Steven E Arnold, MD (1) · Sven Vanneste, PhD (1)
PMID 36117569, PMID 37993889, PMID 38160357
2023 (1), R44AG061981 (1)